Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was downgraded by equities research analysts at TheStreet from a “b-” rating to a “c+” rating in a research note issued on Friday.

A number of other research analysts have also recently commented on the company. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Royal Bank Of Canada increased their price objective on Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. Stifel Nicolaus reduced their price objective on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research note on Tuesday, October 24th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $170.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd. Finally, Leerink Swann reiterated a “buy” rating and issued a $182.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, September 25th. Six research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $154.01.

Alexion Pharmaceuticals (ALXN) opened at $113.45 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a market capitalization of $25,730.08, a price-to-earnings ratio of 23.55, a price-to-earnings-growth ratio of 1.25 and a beta of 1.22.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $864.34 million. During the same period in the prior year, the firm earned $1.23 earnings per share. The firm’s revenue was up 7.5% compared to the same quarter last year. sell-side analysts predict that Alexion Pharmaceuticals will post 4.81 EPS for the current fiscal year.

WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/14/thestreet-downgrades-alexion-pharmaceuticals-inc-alxn-to-c.html.

In related news, EVP Julie O’neill sold 4,375 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total transaction of $636,300.00. Following the transaction, the executive vice president now owns 26,092 shares of the company’s stock, valued at $3,794,820.48. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the transaction, the director now directly owns 5,480 shares in the company, valued at approximately $799,038.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,490 shares of company stock worth $2,337,251. Corporate insiders own 4.35% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Magnetar Financial LLC purchased a new position in shares of Alexion Pharmaceuticals during the third quarter worth about $503,000. Asset Management One Co. Ltd. grew its holdings in shares of Alexion Pharmaceuticals by 2.1% during the third quarter. Asset Management One Co. Ltd. now owns 353,205 shares of the biopharmaceutical company’s stock worth $49,518,000 after buying an additional 7,232 shares during the last quarter. AMP Capital Investors Ltd grew its holdings in shares of Alexion Pharmaceuticals by 11.9% during the third quarter. AMP Capital Investors Ltd now owns 88,361 shares of the biopharmaceutical company’s stock worth $12,396,000 after buying an additional 9,427 shares during the last quarter. Temasek Holdings Private Ltd grew its holdings in shares of Alexion Pharmaceuticals by 3.6% during the third quarter. Temasek Holdings Private Ltd now owns 1,505,325 shares of the biopharmaceutical company’s stock worth $211,182,000 after buying an additional 52,403 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. grew its holdings in shares of Alexion Pharmaceuticals by 2.6% during the third quarter. Nomura Asset Management Co. Ltd. now owns 48,441 shares of the biopharmaceutical company’s stock worth $6,796,000 after buying an additional 1,207 shares during the last quarter. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.